Nachrichten zur Ipsen S.A. Aktie

Ipsen – Half year statement – 2021 12 31

This article or press release has no online content. Please download the associated documents for more information....…

Share buyback program – Ipsen reporting from 13 june to 17 June 2022 – Detailed

This article or press release has no online content. Please download the associated documents for more information....…

Share buyback program – Ipsen reporting from 20 june to 24 June 2022 – Detailed

This article or press release has no online content. Please download the associated documents for more information....…

Share buyback program – Ipsen reporting from 27 june to 01 July 2022 – Agrege

This article or press release has no online content. Please download the associated documents for more information....…

Ipsen – Half year statement – 2022 06 30

This article or press release has no online content. Please download the associated documents for more information....…

Share buyback program – Ipsen reporting from 11 July to 15 July 2022 – Detailed

This article or press release has no online content. Please download the associated documents for more information....…

Ipsen publishes its 2022 half year financial report

This article or press release has no online content. Please download the associated documents for more information....…

Share buyback program – Ipsen reporting from 25 July to 29 July 2022 – Detailed

This article or press release has no online content. Please download the associated documents for more information....…

Share buyback program – Ipsen reporting from 15 to 19 August 2022 – Detailed

This article or press release has no online content. Please download the associated documents for more information....…

Share buyback program – Ipsen reporting from 22 to 26 August 2022 – Detailled

This article or press release has no online content. Please download the associated documents for more information....…

Share buyback program – Ipsen reporting from 29 August to 02 September 2022 – Detailled

This article or press release has no online content. Please download the associated documents for more information....…

Ipsen presents strong full-year 2021 results and enters into exclusive negotiations to divest its Consumer Healthcare business

...…

Ipsen announces investment in new state-of-the-art electronic autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) designed to improve patient experience

Um den gesamten Artikel unter globenewswire.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ipsen delivers a strong sales performance in the first quarter of 2022

Ipsen delivers a strong sales performance in the first quarter of 2022...…

Ipsen receives positive CHMP opinion for Cabometyx® in radioactive iodine-refractory differentiated thyroid cancer

PARIS, FRANCE, 25 March 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human…

Ipsen appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Paris (France), 16 February 2022 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of…

Ipsen initiates a share buy-back program to cover its employee free share-allocation plan

This article or press release has no online content. Please download the associated documents for more information....…

Ipsen receives positive opinion in Europe for Dysport® in the management of urinary incontinence in adults with neurogenic detrusor overactivity due to multiple sclerosis or spinal cord injury

PARIS, FRANCE, 9 June 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that Dysport® (abobotulinumtoxinA) has received positive opinion in…

Ipsen announces results from Phase III RESILIENT trial evaluating Onivyde® in second-line monotherapy for small cell lung cancer

PARIS, FRANCE, 03 August 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Phase III RESILIENT trial did not…

Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022

PARIS, FRANCE, 5 August 2022 – Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its…

Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases

PARIS, FRANCE, 17 May 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from its growing rare…

Ipsen provides update on Phase III CONTACT-01 trial evaluating cabozantinib in combination with atezolizumab in patients with metastatic non-small cell lung cancer previously treated with immunotherapy and chemotherapy

PARIS, FRANCE, 8 December 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the CONTACT-01 study did not meet…

Ipsen – Consolidated Financial Statements – 2022

This article or press release has no online content. Please download the associated documents for more information....…

Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital - April 2023

...…

Ipsen : 2023 CSM - Formalities for making available preparatory documents to the Meeting

INFORMATION RELATING TO THE HOLDING OF THE COMBINED SHAREHOLDERS MEETING OF 31 MAY 2023...…

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance...…

Ipsen appoints new chief medical officer

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs

Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs...…

Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital...…

Ipsen S.A. publishes its 2022 Universal registration document

Regulated Information...…

Ipsen Hunts For Targets With $4.4 Billion to Spend, CEO Says

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Is Cybin Inc. (CYBN) Stock Outpacing Its Medical Peers This Year?

Here is how Cybin Inc. (CYBN) and IPSEN (IPSEY) have performed compared to their sector so far this year....…

New FDA action date in August for Ipsen bone disease drug palovarotene

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP

...…

Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital...…

Is IPSEN (IPSEY) Outperforming Other Medical Stocks This Year?

Here is how IPSEN (IPSEY) and Thermo Fisher Scientific (TMO) have performed compared to their sector so far this year....…

Ipsen Completes Acquisition of Albireo Pharma

Ipsen Completes Acquisition of Albireo Pharma...…

Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio...…

Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023

Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023...…

Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs

Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement…

IPSEN: Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital...…

Ipsen S.A. Non-GAAP EPS of €10.51, revenue of €3.02B; initiates FY23 guidance

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Albireo (ALBO)

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - January 9, 2023) - Law office of Brodsky & Smith announces that it is investigating…

Shareholder Alert: Ademi LLP investigates whether Albireo Pharma, Inc. has obtained a Fair Price in its transaction with Ipsen

MILWAUKEE, Jan. 9, 2023 /PRNewswire/ -- Ademi LLP is investigating Albireo (Nasdaq: ALBO) for possible breaches of fiduciary duty and…

dpa-AFX ProFeed